New mode of treatment for lattice corneal dystrophy type I

Corneal epithelial debridement and fibronectin eye drops

Yukiko Morita, Tai Ichiro Chikama, Naoyuki Yamada, Naoyuki Morishige, Kohei Sonoda, Teruo Nishida

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Purpose: The R124C mutation of the TGFBI gene gives rise to lattice corneal dystrophy type I, which is characterized by irregularity, turbulence, and opacity of the corneal epithelium. We investigated the efficacy of corneal epithelial debridement followed by application of autologous fibronectin eye drops in the treatment of patients with this mutation. Methods: Four patients (6 eyes; age range 25-57 years) treated between April 2006 and March 2008 were enrolled in the study. All patients had impaired visual acuity and recurrent corneal erosion. Corneal epithelial debridement was performed with a spatula at the pupillary zone, after which eye drops containing fibronectin purified from autologous serum were administered four times daily for 2 weeks to promote epithelial migration. Topical levofloxacin and betamethasone were also applied four times daily for 1 month. Results: All corneas achieved resurfacing within a few days of debridement. The best corrected visual acuity of all eyes improved from an average logMAR of 0.80 (range 1.40 logMAR-0.52 logMAR) before treatment to a log-MAR of 0.10 (range 0.30 logMAR-0.046 logMAR) by 2-4 months after debridement. Conclusion: Despite the limitation of this study setting, corneal epithelial debridement followed by administration of fibronectin eye drops seems to be effective in improving visual acuity in cases of lattice corneal dystrophy type I caused by the R124C mutation of the TGFBI gene. This treatment may be one option for temporarily improving visual acuity in lattice corneal dystrophy type I and thus may delay the requirement for phototherapeutic keratoplasty or keratoplasty.

Original languageEnglish
Pages (from-to)26-30
Number of pages5
JournalJapanese Journal of Ophthalmology
Volume56
Issue number1
DOIs
Publication statusPublished - Jan 1 2012
Externally publishedYes

Fingerprint

Ophthalmic Solutions
Debridement
Fibronectins
Visual Acuity
Corneal Transplantation
Mutation
Therapeutics
Betamethasone
Corneal Epithelium
Levofloxacin
Cornea
Genes
Lattice corneal dystrophy type 1
Serum

All Science Journal Classification (ASJC) codes

  • Ophthalmology

Cite this

New mode of treatment for lattice corneal dystrophy type I : Corneal epithelial debridement and fibronectin eye drops. / Morita, Yukiko; Chikama, Tai Ichiro; Yamada, Naoyuki; Morishige, Naoyuki; Sonoda, Kohei; Nishida, Teruo.

In: Japanese Journal of Ophthalmology, Vol. 56, No. 1, 01.01.2012, p. 26-30.

Research output: Contribution to journalArticle

Morita, Yukiko ; Chikama, Tai Ichiro ; Yamada, Naoyuki ; Morishige, Naoyuki ; Sonoda, Kohei ; Nishida, Teruo. / New mode of treatment for lattice corneal dystrophy type I : Corneal epithelial debridement and fibronectin eye drops. In: Japanese Journal of Ophthalmology. 2012 ; Vol. 56, No. 1. pp. 26-30.
@article{d92dca9907bb4a3aaf374e976fbdb606,
title = "New mode of treatment for lattice corneal dystrophy type I: Corneal epithelial debridement and fibronectin eye drops",
abstract = "Purpose: The R124C mutation of the TGFBI gene gives rise to lattice corneal dystrophy type I, which is characterized by irregularity, turbulence, and opacity of the corneal epithelium. We investigated the efficacy of corneal epithelial debridement followed by application of autologous fibronectin eye drops in the treatment of patients with this mutation. Methods: Four patients (6 eyes; age range 25-57 years) treated between April 2006 and March 2008 were enrolled in the study. All patients had impaired visual acuity and recurrent corneal erosion. Corneal epithelial debridement was performed with a spatula at the pupillary zone, after which eye drops containing fibronectin purified from autologous serum were administered four times daily for 2 weeks to promote epithelial migration. Topical levofloxacin and betamethasone were also applied four times daily for 1 month. Results: All corneas achieved resurfacing within a few days of debridement. The best corrected visual acuity of all eyes improved from an average logMAR of 0.80 (range 1.40 logMAR-0.52 logMAR) before treatment to a log-MAR of 0.10 (range 0.30 logMAR-0.046 logMAR) by 2-4 months after debridement. Conclusion: Despite the limitation of this study setting, corneal epithelial debridement followed by administration of fibronectin eye drops seems to be effective in improving visual acuity in cases of lattice corneal dystrophy type I caused by the R124C mutation of the TGFBI gene. This treatment may be one option for temporarily improving visual acuity in lattice corneal dystrophy type I and thus may delay the requirement for phototherapeutic keratoplasty or keratoplasty.",
author = "Yukiko Morita and Chikama, {Tai Ichiro} and Naoyuki Yamada and Naoyuki Morishige and Kohei Sonoda and Teruo Nishida",
year = "2012",
month = "1",
day = "1",
doi = "10.1007/s10384-011-0104-5",
language = "English",
volume = "56",
pages = "26--30",
journal = "Japanese Journal of Ophthalmology",
issn = "0021-5155",
publisher = "Springer Japan",
number = "1",

}

TY - JOUR

T1 - New mode of treatment for lattice corneal dystrophy type I

T2 - Corneal epithelial debridement and fibronectin eye drops

AU - Morita, Yukiko

AU - Chikama, Tai Ichiro

AU - Yamada, Naoyuki

AU - Morishige, Naoyuki

AU - Sonoda, Kohei

AU - Nishida, Teruo

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Purpose: The R124C mutation of the TGFBI gene gives rise to lattice corneal dystrophy type I, which is characterized by irregularity, turbulence, and opacity of the corneal epithelium. We investigated the efficacy of corneal epithelial debridement followed by application of autologous fibronectin eye drops in the treatment of patients with this mutation. Methods: Four patients (6 eyes; age range 25-57 years) treated between April 2006 and March 2008 were enrolled in the study. All patients had impaired visual acuity and recurrent corneal erosion. Corneal epithelial debridement was performed with a spatula at the pupillary zone, after which eye drops containing fibronectin purified from autologous serum were administered four times daily for 2 weeks to promote epithelial migration. Topical levofloxacin and betamethasone were also applied four times daily for 1 month. Results: All corneas achieved resurfacing within a few days of debridement. The best corrected visual acuity of all eyes improved from an average logMAR of 0.80 (range 1.40 logMAR-0.52 logMAR) before treatment to a log-MAR of 0.10 (range 0.30 logMAR-0.046 logMAR) by 2-4 months after debridement. Conclusion: Despite the limitation of this study setting, corneal epithelial debridement followed by administration of fibronectin eye drops seems to be effective in improving visual acuity in cases of lattice corneal dystrophy type I caused by the R124C mutation of the TGFBI gene. This treatment may be one option for temporarily improving visual acuity in lattice corneal dystrophy type I and thus may delay the requirement for phototherapeutic keratoplasty or keratoplasty.

AB - Purpose: The R124C mutation of the TGFBI gene gives rise to lattice corneal dystrophy type I, which is characterized by irregularity, turbulence, and opacity of the corneal epithelium. We investigated the efficacy of corneal epithelial debridement followed by application of autologous fibronectin eye drops in the treatment of patients with this mutation. Methods: Four patients (6 eyes; age range 25-57 years) treated between April 2006 and March 2008 were enrolled in the study. All patients had impaired visual acuity and recurrent corneal erosion. Corneal epithelial debridement was performed with a spatula at the pupillary zone, after which eye drops containing fibronectin purified from autologous serum were administered four times daily for 2 weeks to promote epithelial migration. Topical levofloxacin and betamethasone were also applied four times daily for 1 month. Results: All corneas achieved resurfacing within a few days of debridement. The best corrected visual acuity of all eyes improved from an average logMAR of 0.80 (range 1.40 logMAR-0.52 logMAR) before treatment to a log-MAR of 0.10 (range 0.30 logMAR-0.046 logMAR) by 2-4 months after debridement. Conclusion: Despite the limitation of this study setting, corneal epithelial debridement followed by administration of fibronectin eye drops seems to be effective in improving visual acuity in cases of lattice corneal dystrophy type I caused by the R124C mutation of the TGFBI gene. This treatment may be one option for temporarily improving visual acuity in lattice corneal dystrophy type I and thus may delay the requirement for phototherapeutic keratoplasty or keratoplasty.

UR - http://www.scopus.com/inward/record.url?scp=84858862291&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858862291&partnerID=8YFLogxK

U2 - 10.1007/s10384-011-0104-5

DO - 10.1007/s10384-011-0104-5

M3 - Article

VL - 56

SP - 26

EP - 30

JO - Japanese Journal of Ophthalmology

JF - Japanese Journal of Ophthalmology

SN - 0021-5155

IS - 1

ER -